Lobectomy For Lung Cancer Research Articles

Lobectomy verses Sublobar Resection in The Society of Thoracic Surgeons Database: Importance of Patient Factors and Lymph Node Evaluation.

Prospective randomized trials have demonstrated noninferior survival between sublobar resection and lobectomy in healthy non-small cell lung cancer (NSCLC) patients with tumors ≤2cm. However, some patient attributes are not well represented in randomized trials and uncertainty remains in the widespread applicability of randomized trial nodal dissection protocols. Patients with ≤2cm, node-negative NSCLC (cT1N0) in the Society of Thoracic Surgeons prospective database were linked to Medicare survival data using a probabilistic matching algorithm. Survival was assessed by propensity score weighted Kaplan Meier analysis. Overall, 20,031 patients were identified including 11,976 lobectomy, 2,586 segmentectomy, and 5,469 wedge resection patients. Fewer lymph nodes were sampled in sublobar patients (mean 5.5 vs 12.8) and pathologic upstaging was less common (7.1% vs 14.2%). Overall survival following sublobar and lobar resection was similar within groups under-studied in recent trials including age ≥75 years (p=0.07), FEV1=10-59% (p=0.14), and Zubrod performance status 2-3 (p=0.23). When sublobar resection was performed with inadequate nodal evaluation (<2 nodes removed), the survival was inferior to lobectomy (p<0.001). Among patients with nodal upstaging, lobectomy was not associated with improved survival over sublobar resection (p=0.42). The clinical trial finding that sublobar resections achieve similar survival to lobectomy in early-stage lung cancer appears to apply to older, less healthy patients in a real-world setting, provided adequate lymph node resection is performed. Performing a lobectomy in the setting of nodal upstaging, does not obviously improve survival. Further study is warranted to clarify the role of sublobar resection in the general population.

Postoperative Lung Function Advantages in Pulmonary Segmentectomy for Early-Stage Lung Cancer.

In early-stage lung cancer, lung function appears to be less compromised after segmentectomy than lobectomy, though the advantage seems modest. We aimed to re-assess postoperative lung function in surgical patients, with a particular focus on the diffusion capacity for carbon monoxide (DLCO). We evaluated all patients who underwent either lobectomy or segmentectomy for T1a-c lung cancer at our center between March 2016 and March 2023. From January to June 2024, patients who had undergone segmentectomy, along with a matched cohort of patients who had undergone lobectomy, were invited for a repeat lung function evaluation. Patients were matched 1:1 based on age, sex, surgical approach, year in which the procedure was performed, and tumor location. Lung function testing data including DLCO were then compared to preoperative measures. During the study period, 480 patients received a lobectomy, and 97 received a segmentectomy. Complete lung function evaluation for the study was available for 52 patients (26 matched pairs). The median time from lung resection to repeat spirometry was 35 months. A modest reduction of lung function measures was observed in the segmentectomy group. Conversely, all lung function measures, including DLCO, were significantly impaired in the lobectomy group. In early-stage lung cancer, patients who perform segmentectomy demonstrated better long-term lung function preservation compared to those who underwent lobectomy. Whenever feasible, segmentectomy should be considered the procedure of choice for early-stage lung cancer patients.

Lobectomy vs. bisegmentectomy for lung cancer in the left upper lobe: a retrospective comparative cohort study

Lobectomy vs. bisegmentectomy for lung cancer in the left upper lobe: a retrospective comparative cohort study

Incorporating Lymph Node Size at CT as an N1 Descriptor in Clinical N Staging for Lung Cancer.

Background The ninth edition of the TNM classification for lung cancer revised the N2 categorization, improving patient stratification, but prognostic heterogeneity remains for the N1 category. Purpose To define the optimal size cutoff for a bulky lymph node (LN) on CT scans and to evaluate the prognostic value of bulky LN in the clinical N staging of lung cancer. Materials and Methods This retrospective study analyzed patients who underwent lobectomy or pneumonectomy for lung cancer between January 2013 and December 2021, divided into development (2016-2021) and validation (2013-2015) cohorts. The optimal threshold for a bulky LN was defined based on the short-axis diameter of the largest clinically positive LN at CT. Prognostic differences according to presence of bulky LN in cN1 category for overall survival (OS) were evaluated using multivariable Cox analysis. Survival discrimination was assessed using the Harrell concordance index (C-index). Results A total of 3426 patients (mean age, 64.0 years ± 9.3 [SD]; 1837 male) and 1327 patients (mean age, 63.0 years ± 9.7; 813 male) were included in the development and validation cohorts, respectively. The cutoff size for a bulky LN was established at 15 mm, and the presence of bulky LN was an independent risk factor for OS (hazard ratio [HR], 1.54; 95% CI: 1.10, 2.16; P = .01). In the development and validation cohorts, the cN1-bulky group had higher mortality risk than the cN1-nonbulky group (HR, 2.82 [95% CI: 1.73, 4.58; P < .001]; 2.29 [95% CI: 1.34, 3.92; P = .002], respectively). The bulky LN descriptor improved prognostic discrimination within the cN1 category compared with the current staging (C-index from 0.50 to 0.60 and to 0.58 in the development and validation cohorts [P < .001, P = .006], respectively]). Conclusion Defining bulky LN with a size cutoff of 15 mm was an effective descriptor in the clinical staging of N1 lung cancer. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Horst in this issue.

Risk Factors and Postoperative Complications of Lobectomy for Non-Small Cell Lung Cancer: An Exploratory Analysis of Premedication and Clinical Variables.

Background and Objectives: Postoperative pneumonia and complications significantly impact outcomes in thoracic surgery, particularly for patients undergoing lobectomy for non-small cell lung cancer (NSCLC). This study evaluates whether preoperative premedication influences the risk of postoperative pneumonia and overall complications. Materials and Methods: This retrospective study included 346 patients who underwent lobectomy for NSCLC at the University Hospital Ostrava between 2015 and 2021. Data on demographic variables, tumour staging, surgical approach, and premedication (anticholinergics, benzodiazepines, antihistamines, and analgesics) were analysed. Postoperative outcomes included pneumonia and complications classified by the modified Clavien-Dindo system. Results: Premedication was not significantly associated with postoperative pneumonia (10.7%) or overall complications (26.0%). Tumour size was the only factor significantly associated with complications, with larger tumours increasing the odds (OR: 1.16, p = 0.032). Other factors, including age, ASA classification, BMI, and surgical approach, did not demonstrate significant associations with postoperative outcomes. Conclusions: Premedication does not appear to significantly influence the risk of postoperative pneumonia or overall complications in patients undergoing lobectomy for NSCLC. Similarly, other clinical variables, such as age, ASA classification, BMI, and surgical approach, also did not show significant associations with these outcomes. These findings suggest that premedication can be individualised without increasing postoperative risks. However, tumour size emerged as a significant factor associated with complications, highlighting the need for careful preoperative assessment and planning, particularly in patients with larger tumours.

Prognostic performance of the N category in the 9th edition of lung cancer staging.

To compare the prognostic performance of the N category of lung cancer in the 9th edition with previous editions (7th edition and 8th edition's proposal). Patients who underwent lobectomy or pneumonectomy for lung cancer from January 2015 to December 2021 were retrospectively analyzed. Clinical and pathologic N categories were reclassified according to the 9th edition (N0, N1, N2a, and N2b), the 8th edition's proposal (N0, N1a, N1b, N2a1, N2a2, and N2b), and the 7th edition (N0, N1, and N2). Concordance index (C-index) and calibration were assessed for each edition. A total of 3864 patients were included (962 pN positive and 513 cN positive). The 9th edition demonstrated clear hazard stratification between neighboring pN categories after multivariable adjustment, whereas multiple overlaps were observed in the 8th edition's proposal. It had superior discrimination performance compared with the 7th edition in pathologic staging (all p < 0.05). Compared with the 8th edition's proposal, the 9th edition showed comparable performance in pN2 and overall patients (C-index, 0.560 vs 0.569 [p = 0.163]; 0.666 vs 0.668 [p = 0.396]), In clinical staging, there was no difference in discrimination across 7th to 9th editions (all p > 0.05). N1 dichotomization in the 8th edition's proposal showed discrimination ability (C-index, 0.539 [95% confidence interval: 0.502-0.576]) only in pathologic staging. The calibration was acceptable across the clinical 7th to 9th editions for 5-year survival. The revision of the N category in the 9th edition appears reasonable, offering enhanced prognostic discrimination compared with the 7th edition and comparability to the 8th edition's proposal. Question Does the revised N category in the 9th edition offer added value in discrimination over previous editions? Findings The discrimination performance of the 9th edition is comparable to that of the 8th edition's proposal, demonstrating a distinct hazard stratification between neighboring pN categories. Clinical relevance The revision of the N category in the 9th edition appears reasonable; however, survival heterogeneity within the pathologic N1 category needs to be considered in future updates.

Functional effect of adiponectin and body composition assessment in lung cancer subjects after video-assisted thoracoscopic surgery (VATS) lobectomy.

Lung cancer is a pathology with an important incidence. It is a multifactorial disease characterized by epigenetic and nutritional factors. Indeed, there is a strong association between adipose tissue and the pulmonary system, and low-grade inflammation of obese and/or overweight subjects have a pivotal role in lung cancer establishment. In this study, we analyzed body composition through bioelectrical impedance analysis (BIA) and biochemical parameters such as glycemic and lipidic profile, inflammation profile and adiponectin serum levels in 30 patients (19 male; 11 women) undergoing video-assisted thoracoscopic surgery (VATS) lobectomy for lung cancer from September 2021 to May 2022 at the Thoracic Unit of Luigi Vanvitelli University of Naples. A control group were also recruited (15 male; 15 female) consisting of age and sex matched volunteered subjects at the Thoracic Unit of Luigi Vanvitelli University of Naples. The control group and lung cancer patients were monitored for anthropometric and biochemical parameters before VATS lobectomy. Furthermore, the lung cancer patients were also monitored after 6 months of surgery. Body composition is modified after surgery and also albumin and C-reactive protein (CRP) serum levels. In the overweight patients in our study, adiponectin levels were found to be reduced compared with the control group and increased in the same patients after VATS lobectomy. Tumor removal as well as weight loss could affect adiponectin levels, and thus also a reduction in inflammation. In addition, weight loss could also be due to a psychological condition given by the intervention and not to malnutrition related to therapy.

EE839 New Finding on the Cost-Effectiveness of Robotic-Assisted Lobectomy for Non-Small Cell Lung Cancer

EE839 New Finding on the Cost-Effectiveness of Robotic-Assisted Lobectomy for Non-Small Cell Lung Cancer

Effectiveness of the enhanced recovery after surgery (ERAS) program after lobectomy for lung cancer: a single-center observational study using propensity score matching in Vietnam.

Postoperative complications and extended length of stays (LOS) following lobectomy for non-small cell lung cancer (NSCLC) remain significant healthcare and economic burdens, especially in developing countries with limited resources. This study evaluated the effectiveness of enhanced recovery after surgery (ERAS) protocols in addressing these issues. This observational study compared two groups of patients, utilizing a prospective arm for ERAS and a retrospective arm for routine care. Outcomes measured included postoperative LOS, complications, re-operations, and re-admissions. Propensity score matching (PSM) was used to adjust for potential confounders between the two groups. Among 197 NSCLC patients (98 in the ERAS group and 99 in the routine care group), the PSM resulted in 63 patients in each group. After PSM, the ERAS group experienced a significantly shorter postoperative LOS compared to the routine group (median: 4.6 vs. 5.1 days, P=0.01). There were no significant differences in postoperative complication and re-operative rates between the two groups. However, the ERAS group had a significantly lower postoperative 30-day re-admission rate of 1.6%, compared to 14.3% in the routine care group (P=0.02). In NSCLC patients who underwent lobectomy, ERAS protocols improve postoperative outcomes by reducing LOS and re-admission rates. Therefore, ERAS should be considered a replacement for routine protocols in developing countries to minimize healthcare and economic burdens.

Long-term survival after sleeve lobectomy versus pneumonectomy for non-small cell lung cancer

BackgroundTo compare short-term mortality and long-term overall survival between sleeve lobectomy and pneumonectomy for centrally located non-small cell lung cancer (NSCLC). MethodsWe retrospectively reviewed patients who had been radically resected for NSCLC by sleeve lobectomy with or without pulmonary arterioplasty at our institution between 2009 and 2023. We then propensity score-matched the patients with pneumonectomy counterparts from a national registry and compared their 30- and 90-day mortality and long-term overall survival before and after matching. The mortality was compared using independence tests and the overall survival using Kaplan-Meier estimates and the log-rank test. ResultsThe study included 109 sleeve lobectomy patients and 315 pneumonectomy patients, of whom 60 patients from each group were matched. The 30- and 90-day mortality was similar between both the unmatched and matched groups (unmatched: 3.7 % vs 5.1 % and 5.5 % vs 9.2 %; matched: 5.0 % vs 6.7 % and 5.0 % vs 12 %. All p-values >0.05). The overall survival was longer in both the unmatched and matched sleeve lobectomy patients (unmatched: hazard ratio [HR] 0.52, 95 % confidence interval [CI] 0.37–0.73, p < 0.001; matched HR 0.55, 95 % CI 0.34–0.90, p = 0.018). The 5-year overall survival was 68 % and 49 % for the unmatched sleeve lobectomy and pneumonectomy patients, respectively, and 61 % and 42 % for the matched ones. ConclusionsSleeve lobectomy yields non-inferior short-term mortality and superior long-term overall survival compared with pneumonectomy and should be the resection of choice for centrally located NSCLC when feasible.

Uniportal Robotic Lobectomy and Lymphadenectomy for Invasive Lung Cancer: A Novel Approach and Perioperative Outcomes.

Multiport robot-assisted thoracoscopic surgery (mRATS) has been comprehensively evaluated for its clinical efficacy in numerous studies. Nevertheless, the safety and feasibility of uniportal robotic lobectomy and lymphadenectomy require further validation. The clinical data of 34 consecutive patients with lung cancer who underwent improved uniportal robotic-assisted thoracoscopic surgery (uRATS) at our hospital between November 2023 and June 2024 were reviewed retrospectively. Camera-centered uRATS was conducted using the da Vinci Surgical Xi system (Intuitive Surgical Inc., 1266 Kifer Road, Sunnyvale, CA 94086, USA). Descriptive statistics are expressed as numbers with percentages for categorical data or medians (ranges) or means with standard deviations for continuous data. Improved uRATS lobectomy and lymphadenectomy were conducted in 34 patients with postoperative pathology-diagnosed invasive lung cancer. Among the patients, the median number of lymph nodes dissected was 24.5 (range 10-42), and the median number of stations with lymph nodes dissected was 8 (range 6-11). The median durations of the operation and the uRATS procedure were 200 min (range, 142-330 min) and 140 min (range, 80-242 min), and the median intraoperative blood loss volume was 20 mL (range, 10-100 mL), respectively. All postoperative complications, including pneumonia (2/34, 5.8%), air leakage > 5 days (2/34, 5.8%), prolonged wound healing (1/34, 2.9%), and arrhythmia (1/34, 2.9%), were graded as Clavien-Dindo grades I-II. There were no cases of wound infection or postoperative 30-day mortality. The safety and feasibility of uRATS lobectomy and lymphadenectomy using the da Vinci Surgical Xi system have been preliminarily validated.

A case of right middle lobectomy for primary lung cancer in a patient with heterotaxy syndrome

BackgroundAnatomical abnormalities in the pulmonary vessels have long aroused great interest among thoracic surgeons, and numerous variations of pulmonary vessels have been reported. Heterotaxy syndrome is an anatomical abnormality in which typically asymmetrical organs, including the lungs, develop symmetrically. We report the case of a 71-year-old man with heterotaxy syndrome undergoing radical lobectomy in the treatment of non-small cell lung cancer.Case presentationComputed tomography (CT) revealed an irregular nodule 25 mm in diameter in the right middle lobe. Two months later, at his first visit to our University Hospital, CT revealed a rapidly growing tumor 60 mm in diameter. In addition, three-dimensional (3D) CT revealed the upper and middle lobar bronchi forming a common trunk with the mediastinal type of the right pulmonary artery (PA). The patient underwent video-assisted right middle lobectomy + systematic complete hilar and mediastinal lymph node dissection. The interlobar fissure between the right upper and middle lobes was incomplete, and the common trunk formed by the upper-middle bronchus emerged from an area between the right PA (A1+3) and the right superior pulmonary vein.ConclusionThe finding of A4+5 branching from the right main PA and descending posterior to the right upper-middle bronchus, which formed a common trunk, resembled a mirror image of the normal left lung. To our knowledge, a common trunk with the mediastinal type of the right PA has never been reported during video-assisted right middle lobectomy. In patients with heterotaxy syndrome, 3D-CT to preoperatively understand their anatomy is essential.

Crural Diaphragm Density in Respiratory Complications after Video-Assisted Thoracoscopic Surgery Lobectomy.

Respiratory muscle strength affects pulmonary function after lung resection; however, the role of diaphragm density, an emerging index of muscle quality, remains unexplored. We investigated the role of crural diaphragm density (CDD) in respiratory complications (RC) after video-assisted thoracoscopic surgery (VATS) lobectomy for lung cancer. A total of 118 patients were retrospectively enrolled between 2015 and 2022. Exclusion criteria were neoadjuvant therapy, thoracic trauma, and previous cardiothoracic and abdominal surgery. Demographic, functional, and radiological data were collected. The CDD in Hounsfield Unit (HU) was defined as the average of the density of the right and left crural diaphragm at the level of the median arcuate ligament on computed tomography axial images. RC included sputum retention, respiratory infections, atelectasis, pneumonia, respiratory failure, and acute respiratory distress syndrome. The prevalence of postoperative RC was 41% (48 of 118). RC occurred mostly in males (64.6 vs. 44.3%, p = 0.04), current smokers (41.7 vs. 21.4%, p = 0.02), a longer surgical procedure (210 vs. 180 minutes, p = 0.04), and a lower CDD (42.5 vs. 48 HU, p = 0.05). The optimal cutoff of CDD was 39.75 HU (sensitivity 43%, specificity 82%, accuracy 65%, area under the curve: 0.62, p = 0.05), slightly above the threshold for reduced muscle mass (<30 HU). By multivariable logistic regression a CDD ≤ 39.75 HU (hazard ratio [HR]: 3.134 [95% confidence interval, CI: 1.111-8.844], p = 0.03) and current smoking (HR: 2.733 [95% CI: 1.012-7.380], p = 0.05) were both independent risk factors of postoperative RC. The CDD seems to be a simple and useful tool for predicting RC after VATS lobectomy, especially among current smokers. Such patients, identified early, could benefit from preoperative functional and nutritional rehabilitation.

Effects of combined anesthesia on pulmonary oxygenation function, hemodynamics, and respiratory compliance in elderly patients undergoing pulmonary lobectomy for lung cancer.

Traditional general anesthesia in elderly lung cancer patients undergoing pulmonary lobectomy may lead to hemodynamic fluctuations and postoperative complications. To optimize anesthesia efficacy, this study explores the application of combined anesthesia (general anesthesia combined with thoracic paravertebral block) in such surgeries. We evaluated the improvement of pulmonary oxygenation function, hemodynamic stability, and respiratory compliance in elderly lung cancer patients undergoing pulmonary lobectomy with combined anesthesia. This retrospective study analyzed 100 elderly lung cancer patients who underwent pulmonary lobectomy at our hospital from February 2020 to December 2023. Patients were divided into 2 groups: the control group received general anesthesia, while the treatment group received combined anesthesia (general anesthesia plus thoracic paravertebral block). By comparing intraoperative hemodynamic parameters, postoperative pulmonary oxygenation function, respiratory compliance, cognitive function, sleep quality, and postoperative complication rates between the 2 groups, we assessed the application efficacy of combined anesthesia. Compared to the control group, the treatment group exhibited better hemodynamic stability intraoperatively, significantly improved postoperative pulmonary oxygenation function and respiratory compliance. Additionally, patients in the treatment group showed faster recovery of cognitive function, better sleep quality, and a relatively lower incidence of postoperative complications. Combined anesthesia demonstrates unique advantages in pulmonary lobectomy for elderly lung cancer patients, optimizing intraoperative hemodynamic stability, promoting postoperative pulmonary function recovery, accelerating cognitive function recovery, improving sleep quality, and potentially reducing the risk of postoperative complications. This finding provides a new effective strategy for anesthesia management in elderly lung cancer patients.

Complications and 30-Day Readmission Rates After Lobectomy for Lung Cancer: A Single-Center Pre-enhanced Recovery After Surgery (ERAS) Assessment in Vietnam

Background: This study investigated complications and 30-day readmission rates following lobectomy for lung cancer in a pre-enhanced recovery after surgery (ERAS) program setting at the University Medical Center Ho Chi Minh City, aiming to identify key areas for improvement. Methods: A retrospective analysis was conducted on 99 patients who underwent lobectomy for lung cancer. Data on patient demographics, surgical details, and postoperative outcomes were collected. Complications were categorized using the Clavien-Dindo classification system, and statistical analyses were performed using STATA software. Results: Among the 99 surveyed patients, 53.5% were male, and 46.5% were female, with the majority being over 60 years old. The postoperative complication rate was 19.2% (30.9% reduction with multimodal pain relief, P = 0.001), and the 30-day readmission rate was 13.1% (19.4% reduction with physical therapy before surgery, P = 0.008). High-risk complication factors included open surgery (42.9%) compared to video-assisted thoracoscopic surgery (VATS) (11.8%) (P = 0.026) and vomiting after surgery (46.7%, P = 0.008). Conclusions: The findings underscore the necessity of integrating ERAS principles to enhance postoperative care and outcomes in lung cancer surgery. Implementing ERAS protocols could potentially reduce complications and readmissions, improving patient experiences and surgical efficacy. Future research will focus on applying these insights within the ERAS framework to optimize lobectomy outcomes.

Early Hospital Discharge on Day Two Post-Robotic Lobectomy with Telehealth Home Monitoring.

Background: Despite the implementation of enhanced recovery programs, the reported average postoperative length of stay after robotic lobectomy remains as 4 days. In this prospective study, we present the outcomes of early discharge (on day 2) with telehealth home monitoring device after robotic lobectomy for lung cancer in selected patients. Methods: All patients with a caregiver were discharged on postoperative day 2 (POD 2) with a telemonitoring device provided they met the specific discharge criteria. Inclusion criteria: <75 years old, stage I-II NSCLC, with caregiver, ECOG 0-2, scheduled for lobectomy, logistic proximity to hospital (<60 km); intra-postoperative exclusion criteria: conversion to open surgery, early complications needing hospital monitoring or redo-operation, difficult pain management, <92 HbO2% saturation on room air or need for O2 supplementation, altered vital or laboratory parameters. Teleconsultations were scheduled as follows: the first one in afternoon of POD2, two on POD3, then once a day until chest tube removal. After discharge, patients recorded their vital signs at least four times a day using the device, which allowed two surgeons to monitor them via a mobile application. In the event of sudden changes in vital signs or the occurrence of adverse events, patients had access to a direct phone line and a dedicated re-hospitalization pathway. The primary outcome was safety, assessed by the occurrence of post-discharge complications or readmissions, as well as feasibility. Secondary outcomes: comparison of safety profile with a matched control group in which the standard of care and the evaluation of resource optimization were maintained and economic evaluation. Results: Between July 2022 and February 2024, 48 patients were enrolled in the present study. Six patients (12.5%) dropped out due to unsatisfied discharge criteria on POD2. Exclusion causes were: significant air leaks (n:2) requiring monitoring and the use of suction device, uncontrolled pain (n:2), atrial fibrillation, and occurrence of cerebral ischemia (n:1 each). The adherence rate to vital signs monitoring by patients was 100%. A mean number of four measurements per day was performed by each patient. During telehealth home monitoring, a total of 71/2163 (1.4%) vital sign measurements violated the established acceptable threshold in 22 (52%) patients. All critical violations were managed at home. During the surveillance period (defined as the time from POD 2 to the day of chest tube removal), a persistent air leak was recorded in one patient requiring readmission to the hospital (on POD 13) and re-intervention with placement of a second thoracic drainage due to unsatisfactory lung expansion. No other postoperative complication occurred nor was there any readmission needed. Compared to the control group, the discharge gain was 2.5 days, with an economic benefit of 528 €/day (55.440 € on the total enrolled population). Conclusions: Our results confirm that the adoption of telehealth home monitoring is feasible and allows a safe discharge on postoperative day two after robotic surgery for stage I-II NSCLC in selected patients. A potential economic benefit (141 days of hospitalizations avoided) for the healthcare system could result from the adoption of this protocol.

Comparison of survival between lobectomy and trisegmentectomy for clinical stage T1c-2aN0M0 non-small cell lung cancer in the left upper segment of the lung.

Left upper trisegmentectomy is expected to be as curative as lobectomy for lung cancer because the left upper lobe is anatomically the same as the combined upper and middle lobes of the right lung and the procedure can provide a sufficient surgical margin. In the present multicenter study, we compared the results of trisegmentectomy and lobectomy in patients with clinical stage T1c-2aN0M0 left upper lung cancer. We retrospectively analyzed the outcomes of patients with clinical stage T1c-2aN0M0 lung cancer in the left upper segment who underwent lobectomy or trisegmentectomy between January 2006 and June 2022. The trisegmentectomy group (S group) and lobectomy group (L group) comprised 33 and 132 patients, respectively. Comparisons of postoperative survival revealed no significant differences in overall survival (p = 0.761) or disease-free survival (p = 0.508) between the two groups. There were also no significant differences in survival after adjustment for clinical factors by Cox proportional hazards models and propensity score matching. Local recurrence was significantly more predominant in the S group than in the L group (p = 0.006). The S group had a worse postoperative survival than the L group when the tumor was located in anterior segment. Trisegmentectomy can provide an equivalent postoperative survive to lobectomy in patients with clinical stage T1c-2aN0M0 left upper segment lung cancer except in patients with tumor in anterior segment.

EP.07A.07 Comparison of Inpatient Opioid Use and Pain Control Following Thoracoscopic Segmentectomy Versus Lobectomy for Non-Small Cell Lung Cancer

EP.07A.07 Comparison of Inpatient Opioid Use and Pain Control Following Thoracoscopic Segmentectomy Versus Lobectomy for Non-Small Cell Lung Cancer

Survival Outcomes of Neoadjuvant Therapy Followed by Sleeve Lobectomy in Non-Small Cell Lung Cancer

BackgroundThis study was carried out to evaluate the impact of neoadjuvant therapy on long-term survival of patients with non-small cell lung cancer undergoing sleeve lobectomy. MethodsA total of 613 patients were retrospectively analyzed, including 124 who received neoadjuvant therapy. A 1:2 propensity score matching method was adopted to create a balanced cohort including 110 with neoadjuvant therapy and 169 without neoadjuvant therapy. Survival was estimated by the Kaplan-Meier method and compared with the log-rank test and Cox proportional hazards models. ResultsNeoadjuvant therapy was associated with improved 3-year disease-free survival (DFS; 73.6% vs 54.4%; P < .001) and overall survival (OS; 80.9% vs 63.9%; P = .002) compared with patients without neoadjuvant therapy. Moreover, neoadjuvant chemoimmunotherapy significantly improved 3-year DFS (85.3% vs 54.4%; P = .001) and OS (88.2% vs 63.9%; P = .006), whereas chemotherapy alone did not show a significant effect. Multivariable Cox regression analysis revealed neoadjuvant therapy to be an independent predictor of improved DFS and OS, whereas pathologic N2 stage was independently associated with poorer DFS and OS. Furthermore, subgroup analysis in the neoadjuvant arm revealed that pathologic N2 stage is an independent risk factor for DFS (hazard ratio, 3.830; 95% CI, 1.687-8.694; P = .001), and achieving major pathologic response is an independent predictor for better OS (hazard ratio, 0.120; 95% CI, 0.015-0.933; P = .043). ConclusionsNeoadjuvant therapy before sleeve lobectomy significantly increased DFS and OS in locally advanced non-small cell lung cancer. Sleeve lobectomy is advisable after neoadjuvant therapy, especially following chemoimmunotherapy.

Clinicoradiologic Predictors of Anastomotic Complications After Bronchoplasty for Lung Cancer

BackgroundWe investigated the predictive factors for anastomotic complications in sleeve lobectomy for lung cancer. MethodsBetween February 2008 and April 2023, 196 patients underwent sleeve lobectomy for lung cancer; 140 were included after exclusion of those who underwent extended sleeve lobectomy and salvage surgery after definitive chemoradiotherapy. Clinicopathologic and computed tomography (CT) findings were retrospectively investigated, and predictors of anastomotic complications were analyzed. The CT finding of azygos arch invasion was defined as a compression or stenosis of the azygos arch by the tumor. ResultsLobectomy types were right upper lobectomy in 71 patients, right lower lobectomy in 5, left upper lobectomy in 53, and left lower lobectomy in 11. CT finding of azygos arch invasion was detected in 21 cases. Anastomotic coverage was performed in 41. Bronchial anastomotic complications were observed in 11 patients (7.9%), including 9 with an anastomotic fistula and 2 with stenosis, all of which were on the right side. Only right upper sleeve lobectomy was a significant predictor of anastomotic complications (odds ratio, 5.29; 95% CI, 1.07-26.13). In 71 cases of right upper sleeve lobectomy, anastomotic complications were significantly more frequent (33.3% vs 4.0%; P < .01) and predictive of anastomotic complications when tumor invasion into the azygos arch was detected on CT (odds ratio, 12.00; 95% CI, 2.24-64.42). ConclusionsRight upper sleeve lobectomy is a predictor of anastomotic complications. Particular attention should be paid to anastomotic complications in right upper sleeve lobectomy with suspected tumor invasion of the azygos arch on CT.